About Sonoma Biotherapeutics
Sonoma Biotherapeutics operates as a clinical-stage biotechnology company. It develops adoptive cell therapies for autoimmune and degenerative diseases. It focuses on the research and development of T cell (Treg) therapies for rheumatoid arthritis, inflammatory bowel diseases, and other autoimmune diseases. The company was founded in 2019 and is based in San Francisco, California.
Sonoma Biotherapeutics Patents
Sonoma Biotherapeutics has filed 1 patent.
Clusters of differentiation, Immune system, Autoimmune diseases, Immunology, T cells
Clusters of differentiation, Immune system, Autoimmune diseases, Immunology, T cells
Latest Sonoma Biotherapeutics News
Jul 11, 2023
Disclosures: Amit Garg reports being an advisor for AbbVie, Aclaris Therapeutics, Anaptys Bio, Aristea Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Incyte, InflaRx, Insmed, Janssen, Novartis, Pfizer, Sonoma Biotherapeutics, UCB, Union Therapeutics and Viela Biosciences; receiving research grants from AbbVie, UCB and the National Psoriasis Foundation; and being co-copyright holder of the HS-IGA and HiSQOL instruments. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact email@example.com . Back to Healio Key takeaways: Most patients are treated by nonspecialized health care providers. Comorbidities, health care utilization and costs are increasing for patients with hidradenitis suppurativa, prompting a need for better disease management, according to a study. “Hidradenitis suppurativa (HS) is a chronic, autoinflammatory, recurrent, debilitating skin disease characterized by painful, deep lesions predominantly located in the axillary, inguinal and anogenital regions,” Amit Garg, MD, professor and founding chair of the department of dermatology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, and colleagues wrote. “Current registry data have suggested an increasing incidence in the United States.” Comorbidities, health care utilization and costs are increasing for patients with hidradenitis suppurativa. Image: Adobe Stock. Not only are the incidence rates of HS increasing, but with adalimumab the only biologic approved to treat HS , patients are left with limited treatment options. To better manage this disease, Garg and colleagues evaluated the sociodemographic, clinical and socioeconomic characteristics of patients with HS over a 3-year period. The retrospective study included 10,230 adults (mean age, 47.1 years; 69.8% women), 628 adolescents (mean age, 15.3 years; 84.9% girls) and 51 patients aged younger than 12 years with HS. Results showed that all adolescent patients were covered with commercial insurance, whereas 68.7% of adults had commercial insurance and 31.3% had Medicare. A higher number of HS diagnoses were reportedly given by general practitioners and pediatricians (adults, 41.6%; adolescents, 39.6%) compared with dermatologists (adults, 22.1%; adolescents, 30.6%). Comorbidities At pre-index, the most common Charlson comorbidity among adults at 20.4% was diabetes without complications. This was followed by chronic pulmonary disease at 16.4% and diabetes with complications at 9%. Among adolescents, comorbidities were low except for chronic pulmonary disease at 10.7% in the 2-year post index. Notably, the researchers said this comorbidity was “likely asthma rather than chronic obstructive pulmonary disease.” Elixhauser comorbidities such as uncomplicated hypertension (38.3%), obesity (22.5%), uncomplicated diabetes (19%) and depression (17.4%) were common among adult patients and increased over time. Depression (11%), obesity (10%) and chronic pulmonary disease (8.3%) were high at all time periods for adolescents with depression and obesity increasing over time. Overall, the authors found that the comorbidity burden was high and continued to accumulate even after the approval of biologic therapy. Treatment patterns While surgical procedures were relatively uncommon, incision and drainage were the most frequently used procedures among adults (7.6%) and adolescents (6.4%). Adolescents received more topical and systemic antibiotics than adults (25% vs. 41.7%, 65.1% vs. 74.5%, respectively); however, adults used more analgesics, including opioids to treat HS-related pain, compared with adolescents (10.6% vs. 6.2%). Biologic treatment was an uncommon treatment option, with 3.5% of adults and 1.8% of adolescents utilizing biologics. Health care resource utilization, associated costs All patients reported high utilization of health care resources, with the average number of visits per adult being 10.5 and per adolescent being 6.9 at 1-year pre-index. This study confirmed that most in-office and outpatient visits were not within dermatologic or surgical specialties, as Healio previously reported . “This suggests a possible undermanagement of the disease, with patients being treated by non-specialist [health care providers],” Garg and colleagues wrote. “Given the complexity of HS as a disease, treatment of HS by a non-dermatologist may result in a lack of effective medical treatment, misdiagnosis, or a delay in diagnosis.” At the 2-years post-index time period, total health care costs amounted to $42,143 for adults and $16,057 for adolescents, with outpatient costs being the most. Read more about
Sonoma Biotherapeutics Frequently Asked Questions (FAQ)
When was Sonoma Biotherapeutics founded?
Sonoma Biotherapeutics was founded in 2019.
Where is Sonoma Biotherapeutics's headquarters?
Sonoma Biotherapeutics's headquarters is located at 201, Haskins Way, San Francisco.
What is Sonoma Biotherapeutics's latest funding round?
Sonoma Biotherapeutics's latest funding round is Corporate Minority.
How much did Sonoma Biotherapeutics raise?
Sonoma Biotherapeutics raised a total of $365M.
Who are the investors of Sonoma Biotherapeutics?
Investors of Sonoma Biotherapeutics include Regeneron Pharmaceuticals, 8VC, ARCH Venture Partners, Lilly Asia Ventures, JDRF T1D Fund and 23 more.
Who are Sonoma Biotherapeutics's competitors?
Competitors of Sonoma Biotherapeutics include Karma Biotechnologies and 1 more.
Compare Sonoma Biotherapeutics to Competitors
TxCell is dedicated to the development of therapeutic products for severe chronic inflammatory and autoimmune diseases with hight unmet medical need including inflammatory bowel diseases, inflammatory joint diseases and neurological diseases such as Multiple Sclerosis. The product candidates developed by TxCell consist of antigen-specific Type 1 regulatory cells (Ag-Tregs) generated ex-vivo from patient's peripheral blood in a proprietary manufacturing process (link). The company's lead product candidate, Ovasave, has completed a PI/II clinical trial in Crohn's disease patients, refractory to all current treatments.
TRACT Therapeutics is developing a therapy dedicated to organ transplant success. The therapy involves the isolation and expansion of a patient's own naturally occurring T regulatory cells, known as Tregs.
Cour Pharmaceuticals is developing first-in-class therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease. Its platform of immune-modifying nanoparticles focuses on treating the root cause of immune disease. The company serves clients in the healthcare sector. It was founded in 2015 and is based in Skokie, Illinois.
Parvus Therapeutics is the developer of a class of disease-modifying therapeutics called Navacims. Navacims represent a paradigm shift in treatment approach wherein the immune system is restored to a balanced 'response ready' and immune, self-tolerant state through the induction and abundant systemic expansion of disease-specific type 1 regulatory T (TR1) cells. Parvus has demonstrated disease reversal with Navacims in multiple in vivo disease models.
Quell Therapeutics develops immune cell therapies to target transplant rejection and autoimmune and inflammatory diseases. It uses its Foxp3 Phenotype lock technology, a multi-modular platform, and integrated manufacturing capabilities to design and develop a pipeline of engineered Treg cell therapies. The company was founded in 2019 and is based in London, U.K.
Karma Biotechnologies develops autoimmune therapeutics to improve immune system function. It delivers vaccines to treat autoimmunity, allergies, and food sensitivities. The company was founded in 2017 and is based in Torrance, California.